Saltar al contenido
Merck

Pathogenic variants in the human m6A reader YTHDC2 are associated with primary ovarian insufficiency.

JCI insight (2022-02-10)
Sinéad M McGlacken-Byrne, Ignacio Del Valle, Polona Le Quesne Stabej, Laura Bellutti, Luz Garcia-Alonso, Louise A Ocaka, Miho Ishida, Jenifer P Suntharalingham, Andrey Gagunashvili, Olumide K Ogunbiyi, Talisa Mistry, Federica Buonocore, Berta Crespo, Nadjeda Moreno, Paola Niola, Tony Brooks, Caroline E Brain, Mehul T Dattani, Daniel Kelberman, Roser Vento-Tormo, Carlos F Lagos, Gabriel Livera, Gerard S Conway, John C Achermann
RESUMEN

Primary ovarian insufficiency (POI) affects 1% of women and carries significant medical and psychosocial sequelae. Approximately 10% of POI has a defined genetic cause, with most implicated genes relating to biological processes involved in early fetal ovary development and function. Recently, Ythdc2, an RNA helicase and N6-methyladenosine reader, has emerged as a regulator of meiosis in mice. Here, we describe homozygous pathogenic variants in YTHDC2 in 3 women with early-onset POI from 2 families: c. 2567C>G, p.P856R in the helicase-associated (HA2) domain and c.1129G>T, p.E377*. We demonstrated that YTHDC2 is expressed in the developing human fetal ovary and is upregulated in meiotic germ cells, together with related meiosis-associated factors. The p.P856R variant resulted in a less flexible protein that likely disrupted downstream conformational kinetics of the HA2 domain, whereas the p.E377* variant truncated the helicase core. Taken together, our results reveal that YTHDC2 is a key regulator of meiosis in humans and pathogenic variants within this gene are associated with POI.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-YTHDC2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution